Image: Smiling and playful childImage: Doctor Tom ChauImage: Child playing

Bloorview Research Institute

Scientist Profiles

Name: Evdokia Anagnostou

Evdokia Anagnostou

Title: Clinician Scientist, Bloorview Research Institute

Theme: Evaluation of care

Education:

M.D. Medicine, McGill University (1998)
B.Sc Chemistry, Stevens Institute of technology, 1994
Grad Certificate, Chemical Physiology, Stevens Institute of technology, 1994

University Position:

Assistant Professor, Department of Peadiatrics, University of Toronto

Research Interests:

Neuropsychopharmacology of autism
Neuroimaging of frontostriatal circuitry and social cognition networks in autism

Current Funding:

Intranasal oxytocin for the treatment of children and adolescence with autism spectrum disorders (ASD). (PI: Anagnostou)
Supporting Agency: Department of Defense
Performance Period: 2010-2013
Level of Funding: $ 805,791

A Pilot, Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids in the Treatment of Young Children with Autism; (PI: Anagnostou)
Supporting Agency: Alva Foundation
Performance Period: 2009-2012
Level of Funding: $ 150,000

A pilot, dose finding study of pioglitazone in children with ASD. (PI: Anagnostou)
(On hold by Health Canada)
Supporting Agency: Dean’s Fund
Performance Period: 2010-2011
Level of Funding: $10,000

Memantine vs. placebo for the treatment of motor skill deficits for children with autism; (PI: Anagnostou)
Supporting Agency: Autism Speaks
Performance Period: 2010-2012
Level of Funding: $200,000

A pilot dose finding study of pioglitazone in children with ASD. (PI: Anagnostou)
(On hold by Health Canada)
Supporting Agency: PSI
Performance Period: 2010-2013
Level of Funding: $ 127,700

Biometric Authentication using Handwriting Biomechanics. (PI: Tom Chau)
Supporting Agency: NSERC/ Syngrafii
Performance Period: 2010-2013
Level of Funding: $340,000

Training Grant

CIHR Training Grant in Autism Research.  Fombonne E., Bryson S, Paterson A, Scherer S, Roberts W, Szatmari P, Smith I, Moore C., Anagnostou, E. et al
Supporting Agency: Canadian Institutes of Health Research
Performance Period: 2009 – 2015
Level of Funding: $ 1,950,000

Grants in no cost extension phase:

Title: Brain Glutamate Concentrations in Autistic Adolescents by Magnetic Resonance Spectroscopy ($60,000)
Role: PI
Agency: NARSAD

Title: Brain Glutamate Concentrations in Autistic Children by Magnetic Resonance Spectroscopy ($109,582)
Role: PI
Agency: Autism Speaks

Title: “fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism”
Role: PI
Agency: Mount Sinai School of Medicine GCRC

Title: Intranasal oxytocin for the treatment of social cognition deficits and repetitive behaviors in adults
Role: PI
Agency: Mount Sinai School of Medicine GCRC

Title: Mediators of Motor skill and Praxis in adults with autism spectrum disorder ($83,104)
Role: co-Investigator (PI: Latha Soorya, PhD)
Agency: Autism Speaks

Selected Peer-Reviewed Journal Publications:

Anagnostou E, Miller SP, Guiot MC, Karpati G, Simard L, Dilenge ME, Shevell MI. Type 1 Spinal muscular atrophy may mimic sensory-motor axonal neuropathy. J Child Neurol 2005 20:147-50

Hollander E, Anagnostou E, Chaplin B, Esposito K, Haznedar M, Licalzi E et al. Striatal Volume on MRI and repetitive behaviors in autism. Biological Psychiatry 2005;58:226-32

Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol. 2006;9:209-13

Anagnostou E, Hollander E. Treatment of repetitive behaviors in autism. Current psychiatry, 2006 5:55-64

Anagnostou E., Esposito K., Soorya L., Chaplin W., Wasserman S., Hollander E. Divalproex vs. Placebo Reduces Irritability associated with Fluoxetine administration in autism. Journal of Clinical Psychopharmacology , 2006; 26:444-6

Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, Anagnostou E, Soorya L, Hollander E. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 2006; 21:363-7.

Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S Oxytocin Increases Retention of Social Cognition in Autism. Biol Psychiatry. 2007 15;6:498-503

Guiqing Cai, Lisa Edelmann, Juliet E Goldsmith, Ninette Cohen, Alisa Nakamine, Jennifer G Reichert, Ellen J Hoffman, Danielle M Zurawiechi, Jeremy M Silverman, Eric Hollander, Latha Soorya, Evdokia Anagnostou, Catalina Betancur and Joseph D Buxbaum. Multiplex ligation-dependent probe amplification for genetic screening in autism spectrum disorders: Efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Medical Genomics (In press)

Bryan H. King, M.D.*; Eric Hollander, M.D.; Linmarie Sikich, M.D.; James T. McCracken, M.D.; Lawrence Scahill, M.S.N., Ph.D.; Joel D. Bregman, M.D.; Craig L. Donnelly, M.D.; Evdokia Anagnostou, M.D; Kimberly Dukes, Ph.D.; Lisa Sullivan, Ph.D.; Deborah Hirtz, M.D.; Ann Wagner, Ph.D.; Louise Ritz, M.B.A.; and the STAART Psychopharmacology Network. No effect of Citalopram vs Placebo for Children and Adolescents with Autism Spectrum Disorders and marked levels of repetitive bejaviors. (Accepted for publication, Archives of general psychiatry)

Georgiades S, Papageorgiou V, Anagnostou E. Brief Report: Structure of the Repetitive Behavior Scale-Revised- in a Greek Sample. J Autism Dev Disord. 2010 Jan 28.

Hollander, E., Chaplin,W.,  Soorya,L.,  Wasserman,S., Novotny,S., Rusoff, J., Feirsen,  N., Anagnostou. E.,  Divalproex sodium vs. placebo for the treatment of irritability in Children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010 Mar;35(4):990-8.

Books and Chapters in Books
Anagnostou, E., Bear. M. & Dawson, G. Commentary: Future directions in the treatment of autism spectrum disorders. In: David Amaral, Geraldine Dawson & Daniel Geschwind (Eds), Autism Spectrum Disorders. Oxford University Press, (In press).

Anagnostou E, Rusoff J. Anticonvulsants in the treatment of Autism.  In: Hollander E, Kolevzon A, Coyle J. (Eds), Autism, APPI press, (In press)

Anagnostou E, Bear M, Dawson G. Future: the path to better treatments. In : Amaral, Dawson, and Geschwind (Eds) Autism Spectrum Disorders,  Oxford University Press (In press)

Clinical Manual for the Treatment of Autism.  Eds: Hollander E, Anagnostou E,  American Psychiatric Publishing, Inc. 2007

Anagnostou E., Shevell M. Outcomes in Autism. In:  Autism: A neurological disorder of early brain development.  Mac Keith Press. 2006

Hollander, E., Swanson, E., Anagnostou, E., Phillips, A., Chaplin, W., Wasserman, S. Liquid fluoxetine vs. placebo for repetitive behaviors in childhood autism. In J. Cummings (Ed.), Progress in Neurotherapeutics and Neuropsychopharmacology. (pp 105-113.). Cambridge University Press.  2006,

Anagnostou E., Hollander E. Autism spectrum Disorders. In:  Neurological and Psychiatric disorders. Humana Press. 2005

Contact Information:
Bloorview Research Institute,
Holland Bloorview Kids Rehabilitation Hospital
150 Kilgour Road
Toronto, Ontario M4G 1R8

Tel: 416-425-6220, extension 6005

E-mail: eanagnostou (at) hollandbloorview (dot) ca (see Note below)*

*Note: Copy the above e-mail address(es) into the To field of your e-mail message and reconstruct the e-mail address(es) by removing the spaces and replacing the “at” and “dot” with the proper symbols (@ and .) respectively.

Back to Scientist Profiles